EUCTR2021-000357-26-FI进行中（未招募）1 期
A Phase III, randomized, multi-country study to evaluate the lot-to-lot consistency of GSK’s investigational RSV maternal vaccine and the immune response, safety and reactogenicity of RSV maternal vaccine when co-administered with GSK’s quadrivalent influenza D-QIV vaccine in healthy non-pregnant women 18-49 years of age. - RSV MAT-010
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,541
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study specific procedure.
- •Healthy female participants; as established by medical history and clinical examination, aged 18 to 49 years at the time of the first study intervention administration.
- •- Female participants of childbearing potential may be enrolled in the study, if the participant:
- •- has practiced adequate contraception for 1 month prior to study intervention administration, and
- •- has a negative pregnancy test on the day of study intervention administration, and
- •- has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration.
- •No local condition precluding injection in both left and right deltoid muscles.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1541
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Medical conditions
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions;
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination;
- •Current autoimmune disorder, for which the participant has received immune-modifying therapy within 6 months, before study vaccination;
- •Hypersensitivity to latex;
- •Acute or chronic clinically significant abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions, as determined by physical examination or medical history that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study;
- •Significant or uncontrolled psychiatric illness;
- •Recurrent history or uncontrolled neurological disorders or seizures;
- •Documented HIV-positive participant;
- •Body mass index> 40 kg/m^2;
- •Any clinically significant* hematological parameter and/or biochemical laboratory abnormality.
- •*The investigator should use his/her clinical judgment to decide which abnormalities are clinically significant.
- •Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
- •Prior/Concomitant therapy
- •Use of any investigational or non-registered product other than the study intervention(s) during the period starting 30 days before study intervention (Day -29 to Day 1), or planned use during the study period;
- •Administration of long-acting immune-modifying drugs at any time during the study period;
- •Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the study intervention or planned administration during the study period;
- •Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s). For corticosteroids, this will mean prednisone 5 mg/day, or equivalent. Inhaled and topical steroids are allowed;
- •Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after the vaccination dose;
- •Administration of a seasonal influenza vaccine during the 6 months preceding entry into the study;
- •Previous experimental vaccination against RSV.
- •Prior/Concurrent clinical study experience
- •Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product;
- •Other exclusions
- •Pregnant or lactating female;
- •Female planning to become pregnant or planning to discontinue contraceptive precautions;
- •Alcoholism or substance use disorder within the past 24 months based on the presence of two or more of the following abuse criteria: hazardous use, social/interpersonal problems related to use, neglected major roles to use, withdrawal tolerance, use of larger amounts or longer, repeated attempts to quit or control use, much time spent using, physical or psychological problems related to use, activities given up to use, craving;
- •Any study personnel or their immediate dependents, family, or household members.
研究者
相似试验
已完成
3 期
A Multinational, Randomized, Phase III Study of XELIRI with/without Bevacizumab versus FOLFIRI with/without Bevacizumab as Second-line Therapy in Patients with Metastatic Colorectal Cancer.Patients with 2nd-line treatment of mCRCJPRN-UMIN000012263PO Epidemiological and Clinical Research Information Network (ECRIN)600
进行中（未招募）
不适用
Immunogenicity, safety and reactogenicity study of GlaxoSmithKline (GSK) Biologicals’ Hib-MenCY-TT vaccine compared to monovalent Hib vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.Invasive disease caused by Haemophilus type b and Neisseria meningitidis serogroups C and YMedDRA version: 18.0Level: LLTClassification code 10028910Term: Neisseria meningitides meningitisSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10051931Term: Neisseria infection NOSSystem Organ Class: 100000004862EUCTR2005-002352-18-Outside-EU/EEAGlaxoSmithKline Biologicals4,441
进行中（未招募）
1 期
ICON9 is a research study investigating patients with recurrent ovarian, fallopian tube or primary peritoneal cancer, who have had their tumour shrunk by chemotherapy. The study will address whether such patients may benefit from maintenance treatment with two new anti-cancer, orally-administrated drugs called olaparib and cediranib.EUCTR2017-000161-75-GBniversity College London618
进行中（未招募）
不适用
MULTINATIONAL, PHASE III, RANDOMIZED STUDY TO EVALUATE TREATMENT CUSTOMIZED ACCORDING TO RAP 80 AND BRCA1 mRNA ASSESSMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (modification of the BREC study) - BRECEUCTR2007-004278-20-FRADDS (Advanced Drug Development Services)480
招募中
3 期
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients.Fallopian tube CancerPeritoneal CancerCancer - Ovarian and primary peritonealOvarian CancerACTRN12618000498291The University of Sydney110